NMR screening to select compounds that interact with human frataxin.
Job details; type Fellowship, Università degli Studi di Roma Tor Vergata, Italy. Expires: February 06, 2014
Friedreich Ataxia and close related scientific news. Topics related to rare diseases.
Sunday, February 2, 2014
Graduate student seminar: “Frataxin Stimulates Fe/S Cluster Biosynthesis.”
“Frataxin Stimulates Fe/S Cluster Biosynthesis.”
February 13 @ 12:45 pm - 1:45 pm
Yu Wang will present her PhD research seminar entitled, “Frataxin Stimulates Fe/S Cluster Biosynthesis.”
February 13 @ 12:45 pm - 1:45 pm
Yu Wang will present her PhD research seminar entitled, “Frataxin Stimulates Fe/S Cluster Biosynthesis.”
Sex differences in mitochondrial biogenesis determine neuronal death and survival in response to oxygen glucose deprivation and reoxygenation
Sex differences in mitochondrial biogenesis determine neuronal death and survival in response to oxygen glucose deprivation and reoxygenation; Jaswinder Sharma, Michael V Johnston and Mir Ahamed Hossain; BMC Neuroscience 2014, 15:9 doi:10.1186/1471-2202-15-9
OPEN ACCESS
OPEN ACCESS
Spongionella Secondary Metabolites Protect Mitochondrial Function in Cortical Neurons against Oxidative Stress
Spongionella Secondary Metabolites Protect Mitochondrial Function in Cortical Neurons against Oxidative Stress.Leirós M, Sánchez JA, Alonso E, Rateb ME, Houssen WE, Ebel R, Jaspars M, Alfonso A, Botana LM.; Mar Drugs. 2014 Jan 27;12(2):700-18. doi: 10.3390/md12020700.
Oxidative stress is linked to mitochondrial dysfunction and consequently to neurodegenerative disorders like Parkinson and Alzheimer diseases, Friedreich ataxia or Amyotrophic lateral sclerosis. This neuroprotection against oxidation conditions suggest that these metabolites could be interesting lead candidates in drug development for neurodegenerative diseases.
FULL TEXT
Oxidative stress is linked to mitochondrial dysfunction and consequently to neurodegenerative disorders like Parkinson and Alzheimer diseases, Friedreich ataxia or Amyotrophic lateral sclerosis. This neuroprotection against oxidation conditions suggest that these metabolites could be interesting lead candidates in drug development for neurodegenerative diseases.
FULL TEXT
Mitochondrial ferritin in the regulation of brain iron homeostasis and neurodegenerative diseases
Mitochondrial ferritin in the regulation of brain iron homeostasis and neurodegenerative diseases. Gao G and Chang Y (2014).Front. Pharmacol. 5:19. doi: 10.3389/fphar.2014.00019
FULL TEXT
FULL TEXT
Stem cells therapy for regenerative medicine: Principles of present and future practice
Stem cells therapy for regenerative medicine: Principles of present and future practice. Andrades, J. , Becerra, J. , Muñoz-Chápuli, R. , Martínez, S. , Raya, Á. , García-Sancho, J. and Moraleda, J. (2014); Journal of Biomedical Science and Engineering, 7, 49-57. doi: 10.4236/jbise.2014.72008.
OPEN ACCESS
The use of stem cells as a therapeutic tool for a number of ischemic, inflam-matory, autoimmune, metabolic and degenerative dis-eases represents one of the more promising areas of bio-medical research; however, after more than 15 years of an exponential increase in basic knowledge, the promise to translate all those findings to clinical practice has not been achieved. There is only one cell therapy product that has obtained market authorization in the EU, and despite several hundred of phase I-II clinical trials there is almost a complete lack of robust efficacy data from phase III trials.
Salvador Martinez’s group (University of Alicante) has analyze the effect that bone marrow and adipose mesenchymal stem cells (MSCs) grafts exert in a chronic demyelination and Friedrich ataxia mice models. As a result, oligodendrocyte progenitors were detected sur- rounding the graft in experimental demyelinating brain models, as well as increasing of dorsal root ganglia cells survival in vitro Friedrich ataxia cellular and animal models. This potential therapeutic effect was due to a selective production of trophic factors by the MSCs.
OPEN ACCESS
The use of stem cells as a therapeutic tool for a number of ischemic, inflam-matory, autoimmune, metabolic and degenerative dis-eases represents one of the more promising areas of bio-medical research; however, after more than 15 years of an exponential increase in basic knowledge, the promise to translate all those findings to clinical practice has not been achieved. There is only one cell therapy product that has obtained market authorization in the EU, and despite several hundred of phase I-II clinical trials there is almost a complete lack of robust efficacy data from phase III trials.
Salvador Martinez’s group (University of Alicante) has analyze the effect that bone marrow and adipose mesenchymal stem cells (MSCs) grafts exert in a chronic demyelination and Friedrich ataxia mice models. As a result, oligodendrocyte progenitors were detected sur- rounding the graft in experimental demyelinating brain models, as well as increasing of dorsal root ganglia cells survival in vitro Friedrich ataxia cellular and animal models. This potential therapeutic effect was due to a selective production of trophic factors by the MSCs.